Venatorx Pharmaceuticals speaks with ContagionLive about our pipeline, our long-term view for our company, and how the federal government’s use of the nomenclature innovation might actually hinder incremental improvements in antibiotic development.

An improved economic model is needed, one that incentivizes and supports antibiotic innovation and ensures that medicines are available when needed and new drugs are constantly in the pipeline. Venatorx weighs in...

GARDP was able to make progress in 2020 despite the challenges of the COVID-19 pandemic. This webinar highlighted efforts to advance antibiotic R&D in the midst of the pandemic and underscored the importance of investing in the development of new and improved treatments for drug-resistant infections that pose the greatest threat to health.

Several Philadelphia-area life sciences companies made significant progress this week with development of new drug candidates targeting heart disease and viral and bacterial pathogens including Covid-19. Here's a rundown.

When old antibiotics become ineffective, we need new, cutting-edge drugs to replace them. Yet the high-risk nature of antibiotic R&D can deter even the most hopeful investor from funding much-needed projects.

What happens when antibiotics stop working? Antimicrobial resistance (AMR) can have devastating effects. New developments in drug trials could see an innovative medical mechanism against AMR become a reality bringing hope to those with no other choice

For the long-term viability of this sector, we need a product success story. We need good data that the product gets used in the marketplace and patients have positive outcomes. That’s a longer journey but also the ultimate victory: A product that actually does well in the marketplace.

It's important not only to find the smartest people they could, but also people who could work in a team environment with a collaborative spirit and one goal in mind: to get therapies into the hands of physicians to effectively treat patients.

Big4Bio spoke Christopher Burns, founder, president and CEO of Venatorx, about the need for new means of combating multi-drug resistant microbes, the company’s combination therapies in development, and its success at advancing its pipeline with non-dilutive funding.

The discovery and advancement of highly potent CpAMs represents an exciting opportunity to achieve deeper and more complete levels of antiviral suppression in chronic HBV patients. This has the potential to form the basis for future combination therapies that lead to a functional cure.

By circumventing over 80 years of beta-lactamase-driven resistance, this new class of PBP Inhibitors has the potential to usher in a new wave of antibacterial therapeutics targeting multi-drug resistant bacteria.

The antibiotic market is dominated by a class of compounds known as beta-lactams, which include many commonly used antibiotics (penicillins, cephalosporins, and carbapenems), and make up about 78 percent of the $35 billion global market.

When a very sick patient comes into the hospital, the doctor often doesn’t know right away what bacteria the patient has. Lab tests take days and doctors usually prescribe something with broad coverage until they can narrow down the cause of infection.

A Chester County pharmaceutical company has selected a clinical candidate it intends to develop as a treatment for chronic hepatitis B virus infections.

The National Institutes of Health (NIH) provides significant funding for drug development research. Across the Pharm Country Hotbed, the agency has provided hundreds of millions of dollars to universities, research institutes and pharmaceutical companies.